Market research
DTIL Precision BioSciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 244M
- P/E ratio
- Not available
- Analyst target
- 29.4
- Dividend yield
- Not available
- Beta
- 1.23
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US74019P2074
- Market cap
- 244M
- P/E ratio
- Not available
- Analyst target
- 29.4
- Dividend yield
- Not available
- Beta
- 1.23
About
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the DTIL discussion.
5 years, 4 months ago
Precision BioSciences, Inc is currently in a long term uptrend where the price is trading 16.5% above its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.8.
Precision BioSciences, Inc's total revenue rose by 35.6% to $9M since the same quarter in the previous year.
Its net income has dropped by 12.1% to $-23M since the same quarter in the previous year.
Finally, its free cash flow grew by 44.2% to $-15M since the same quarter in the previous year.
Based on the above factors, Precision BioSciences, Inc gets an overall score of 4/5.